Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-07-16

Clinical Trial Update: 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857) [Phase 3]

View source ↗

Summary

Phase 3 40-week extension study of asenapine and olanzapine for bipolar disorder has completed with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Asenapine (asenapine)
  • olanzapine (olanzapine)

Snippet

Sponsor: Organon and Co | Conditions: Bipolar Disorder | Phase 3 | Status: COMPLETED | Results posted: 2010-07-16